•  
  •  
  •  
  •  

2022-08-08 07:23:17

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • AVRO India Ltd posts Rs. 1.04 crore profit in Q1FY23
  • L&T donates a bus to Sankara Eye Hospital for their outreach programme
  • Rushil Decor Ltd to raise Rs. 200 crores through rights issue
  • Cineline India opens 4 - Screen multiplex, MovieMAX Gaziabad, Uttar Pradesh
  • Bayer Cropscience - Q1FY23 Result Update - Good set of numbers in challenging scenario - Accumulate

Keywords Selected:  DrReddysLaboratories

Research

  • Dr. Reddy's Laboratories - Analyst Meet Update - Multiple growth initiatives - BUY

Stock Report

  • Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma
  • Dr Reddys Laboratories Ltd consolidated Q1FY2023 net profit surges to Rs. 1187.6 crores
  • Dr. Reddy's Laboratories launches Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market
  • Dr. Reddy's announces the first-to-market launch of over-the-counter, store-brand equivalent of Allegra-D® 24 HR in the U.S. Market
  • Dr. Reddy's Labs launches Fesoterodine Fumarate Extended-Release Tablets in the U.S. market
  • Dr. Reddy's Laboratories updates on PAI of formulations facility
  • Dr. Reddy's Laboratories announces conclusion of patent litigation with Indivior Inc
  • Dr. Reddy's Laboratories announces the acquisition of an injectable product portfolio from Eton Pharma
  • Dr. Reddy's Laboratories Limited enters into settlement agreement with Indivior Inc
  • Dr. Reddy's Laboratories announces launch of the generic version of Nexavar in the U.S. market
  • Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies
  • Torrent Pharma acquires 4 Brands from Dr. Reddy's Laboratories
  • Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announces the launch Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market
  • Dr. Reddys Laboratories Ltd recommends final dividend of Rs. 30
  • Dr. Reddys Laboratories Q4FY22 consolidated net profit slides to Rs. 87.5 crores
  • Dr. Reddy's Laboratories enters into exclusive partnership with HK inno.N Corporation
  • Dr. Reddy's Laboratories announces the launch of Posaconazole Delayed-Release Tablets in the U.S. Market
  • Dr. Reddy's to acquire cardiovascular brand Cidmus® in India
  • Dr. Reddy's Laboratories updates on acquisition of Nimbus Health GmbH
  • Binnopharm Group enters into agreement to acquire two anti-bacterial brands from Dr. Reddy's in the Russia & CIS region
  • Dr. Reddy's Laboratories Ltd receives EIR from USFDA for Vizag unit
  • Dr. Reddy's Laboratories enters into exclusive sales and distribution agreement with Novartis India Limited for select India brands
  • Dr. Reddy's Laboratories Ltd updates on New York plant audit
  • Dr. Reddy's Laboratories launches its authorized generic version of VASOSTRICT® Vials in the U.S. Market

Latest Post

  • AVRO India Ltd posts Rs. 1.04 crore profit in Q1FY23
  • L&T donates a bus to Sankara Eye Hospital for their outreach programme
  • Rushil Decor Ltd to raise Rs. 200 crores through rights issue
  • Cineline India opens 4 - Screen multiplex, MovieMAX Gaziabad, Uttar Pradesh
  • Bayer Cropscience - Q1FY23 Result Update - Good set of numbers in challenging scenario - Accumulate


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
No:AP-172, 2nd Sector, 10th Street, KK Nagar
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

Disclaimer Copyright © - 2021